| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 95,474 | 160,101 |
| Proceeds from underwritten sales of common stock, net of issuance costs | - | 0 |
| Proceeds from issuance of long-term debt | - | 0 |
| Proceeds from atm sales of common stock, net of issuance costs | 17,300 | 17,300 |
| Payment of debt issuance costs | - | 0 |
| Payments related to net settlement of restricted share awards | -37 | -37 |
| Proceeds from exercise of warrants | 5,163 | - |
| Net cash provided by financing activities | 22,426 | 17,263 |
| Net increase in cash, cash equivalents and restricted cash | 59,527 | 140,178 |
| Cash and cash equivalents at beginning of period | 23,695 | - |
| Cash and cash equivalents at end of period | 83,222 | - |
ABEONA THERAPEUTICS INC. (ABEO)
ABEONA THERAPEUTICS INC. (ABEO)